Skip to content
OpenCapital
Get started

Adaptive Biotechnologies ADPT Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$5.2M+528%

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$3.1B+93.6%
Enterprise value$3.23B+78.0%
P/S10.5×+2.0×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity1×-0.2×
Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's increase (decrease) in contract liabilities and current deferred income?
Adaptive Biotechnologies (ADPT) reported increase (decrease) in contract liabilities and current deferred income of $4M in Q1 2026.
How has Adaptive Biotechnologies's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Adaptive Biotechnologies's increase (decrease) in contract liabilities and current deferred income increased by 220.4% year-over-year, from -$3.33M to $4M.
What is the long-term trend for Adaptive Biotechnologies's increase (decrease) in contract liabilities and current deferred income?
Over 4 years (2021 to 2025), Adaptive Biotechnologies's increase (decrease) in contract liabilities and current deferred income has grown at a -8.5% compound annual growth rate (CAGR), from -$57.73M to -$40.4M.